Among patients with non-small cell lung cancer (NSCLC)
fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating
tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased
progression - free survival.